Scott has been covering Jim Cramer and Mad Money for The Street since 2006, providing a nightly recap of the show and the Lightning Round as well as maintaining The Street's exclusive Mad Money Stock Screener.
Jim Cramer weighs in on Pfizer, eBay, Cloudera, Cadence Systems, CRISPR Therapeutics, Moderna, Tandem Diabetes Care, and more.
Jim Cramer says higher sales, higher prices, and demand from emerging markets seem to be fueling a return to the days of great senior growth stocks.
Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.
Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.
Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.
Jim Cramer weighs in on Coca-Cola, Tesla, EPR Properties, Six Flags, Community Bank System, Alder Biopharmaceuticals and more.
Jim Cramer says the consumer economy is in great shape, but the business economy is a different story. He wants the Fed to pay attention.
Jim Cramer weighs in on Waste Management, Idexx Laboratories, TriplePoint Venture Growth, Cato Corp., Paycom Software, New Residential Investment and more.
Jim Cramer looks at Symantec, Clorox, United Rentals, Qualys, Malibu Boats, Illumina and more.
Jim Cramer says no one ever got hurt taking a profit, but it looks like this is a market worth running to when the stocks of good companies go down.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.